We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
– Hepatic arterial infusion (HAI) of nelitolimod has been well tolerated and associated with encouraging immunologic activity in patients with HCC and ICC – 4 mg dose demonstrated 3 of 3 patients...
TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients...
Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported gross margin of 85% in 1Q24 Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion...
– Accomplished industry veteran brings deep strategic and operational expertise TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with...
Call Scheduled for Wednesday, May 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to...
$25 million funded at close; up to $25 million of additional capital available at the Company’s option, based on the achievement of certain revenue thresholds Capital from the transaction is...
Reported revenues of $5.7 million in 4Q23, up 77% over prior year Full year revenues of $18.5 million, up 49% over prior year Gross Margin of 90% in 4Q23 and 86% for full year CMS reimbursement...
– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery...
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors...
– Q4 sales of approximately $5.7 million represent 77% growth versus 2022 – – Q4 and full year gross margin of approximately 90% and 86% respectively – – Full year 2024 sales growth expected to...
| Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.14 | -2.40137221269 | 5.83 | 6.18 | 5.61 | 33463 | 5.75158805 | CS |
| 4 | -3.31 | -36.7777777778 | 9 | 9 | 5.61 | 57444 | 7.03724628 | CS |
| 12 | -4.1 | -41.8794688458 | 9.79 | 10.42 | 5.61 | 42676 | 8.57401758 | CS |
| 26 | -2.5 | -30.525030525 | 8.19 | 10.42 | 5.61 | 39083 | 8.85743654 | CS |
| 52 | -8.11 | -58.768115942 | 13.8 | 16.24 | 3.32 | 51915 | 7.49158573 | CS |
| 156 | -8.11 | -58.768115942 | 13.8 | 16.24 | 3.32 | 51915 | 7.49158573 | CS |
| 260 | -8.11 | -58.768115942 | 13.8 | 16.24 | 3.32 | 51915 | 7.49158573 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
